GLG Pharma, a biotechnology company is developing a series of patented compounds designed to inhibit and cause the degradation of an important pathway protein that all cells use but is highly conserved or controlled by normal cells, that protein is called, Signal Transducer and Activators of Transcription 3 (STAT3). The compounds that bind to STAT3 and cause its degradation are exclusively licensed from the Moffitt Cancer Center & Research Institute, Tampa FL. as well as the Dana Farber Cancer Institute in Boston, MA and with a recent jointly developed patented STAT3 product with the National Cancer Institute (NCI). STAT3 compounds are a new generation of targeted therapies. Four inhibitors have been selected for development and are in advanced preclinical stage and one is in Phase 2a evaluation for the control of resistant Chronic Lymphocytic Leukemia (CLL).
Clarity and purpose
Our focus at GLG Pharma is to discover and develop new drugs that will dramatically expand and improve current treatment options for patients with cancer. Our story starts with our vision, which reflects who we are, where we’re going and what we’re trying to do. Our mission and values keep us focused on the kind of company—and people—we want to be.
Our vision is to transform the lives of cancer patients with breakthrough medicines.
Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need—aggressive cancers where current therapies are inadequate. We are committed to the highest standards of integrity and stewardship in service to patients, the medical community, employees, and shareholders.
Our corporate values reflect what we believe in and stand for:
Mutual respect—we seek always to recognize and acknowledge every individual perspective.
Integrity—we strive for honesty and transparency in our behavior, every day.
Scientific excellence—we value innovation, creativity, and individual initiative in our work.
Teamwork—we believe in collaborative relationships and shared success.
Clinical scholarship—our unique approach to clinical investigation aims at addressing the biological basis of disease.
Execution—we are committed to acting decisively and delivering on our commitments in all we do.
Meet Our Team
CEO, Co-Founder, BS, MBA
Richard is one of the co-founders of GLG Pharma along with Hector Gomez and Michael Lovell (who passed from brain cancer). He has a B.S. in Chemistry and an Executive MBA. He is an avid antiquarian book collector (and sometimes dealer), specializing in early Americana and rare first editions. He enjoys the outdoors, nature, gardening, and drug discovery and development.
Hector J. Gomez
CMO, Co-Founder; MD, PhD
Hector has over 40 years of drug development expertise, leading the charge at firms such as Merck, Pharmacia, Vertex, and has obtained approvals on 11 medicines on a global scale. Hector enjoys his very large family and the out doors as well as traveling through South America and Europe.